Kevin Tang bought $14M of AUPH
director at Aurinia Pharmaceuticals Inc.. 1,300,000 shares at an average of $10.45, traded Aug 1, 2025, filed Aug 5, 2025.
Score components
- +15RoleDirector
- +25Trade size$13.6M at market
- +3Relative to holdingsHoldings up 13%
- 0Price contextMid range
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-021066, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 1, 2025 | POpen-market purchase Common Sharesindirect: By LP | +1,000,000 | $10.12 | $10M | 11,029,500 | Aug 5, 2025 |
| Aug 4, 2025 | POpen-market purchase Common Sharesindirect: By LP | +100,000 | $11.34 | $1.1M | 11,129,500 | Aug 5, 2025 |
| Aug 5, 2025 | POpen-market purchase Common Sharesindirect: By LP | +200,000 | $11.68 | $2.3M | 11,329,500 | Aug 5, 2025 |
Related signals
Other insiders at Aurinia Pharmaceuticals Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 27Weak | AUPHsell Aurinia Pharmaceuticals Inc. | Stephen P. Robertson Chief Legal Officer | $190k 11,939 shares | -2% | |
| 32Weak | AUPHsell Aurinia Pharmaceuticals Inc. | Greg Keenan Chief Medical Officer | $210k 20,000 shares | -13% | |
| 38Weak | Aurinia Pharmaceuticals Inc. | Greg Keenan Chief Medical Officer | $68k 8,305 shares | -5% | |
| 48Moderate | AUPHbuy Aurinia Pharmaceuticals Inc. | Kevin Tang director | $13M 1,600,000 shares | +19% | |
| 65Notable | Aurinia Pharmaceuticals Inc. | Matthew Maxwell Donley Chief Operating Officer | $994k 124,893 shares | -16% | |
| 60Notable | Aurinia Pharmaceuticals Inc. | Stephen P. Robertson EVP, General Counsel | $975k 122,479 shares | -19% | |
| 66Notable | Aurinia Pharmaceuticals Inc. | Joseph M Miller Chief Financial Officer | $940k 118,013 shares | -17% | |
| 40Moderate | Aurinia Pharmaceuticals Inc. | Greg Keenan Chief Medical Officer | $98k 12,239 shares | -7% | |
| 70Notable | Aurinia Pharmaceuticals Inc. | Peter Greenleaf Chief Executive Officer | $2.9M 360,540 shares | -17% | |
| 43Moderate | AUPHbuy Aurinia Pharmaceuticals Inc. | Kevin Tang director | $11M 1,200,000 shares | +17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.